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Abstract 
Optical energy can trigger a variety of photochemical processes useful for therapies. Owing to the 
shallow penetration of light in tissues, however, the clinical applications of light-activated therapies 
have been limited. Bioluminescence resonant energy transfer (BRET) may provide a new way of 
inducing photochemical activation. Here, we show that efficient bioluminescence energy-induced 
photodynamic therapy (PDT) of macroscopic tumors and metastases in deep tissue. For mono-
layer cell culture in vitro incubated with Chlorin e6, BRET energy of about 1 nJ per cell generated as 
strong cytotoxicity as red laser light irradiation at 2.2 mW/cm2 for 180 s. Regional delivery of 
bioluminescence agents via draining lymphatic vessels killed tumor cells spread to the sentinel and 
secondary lymph nodes, reduced distant metastases in the lung and improved animal survival. Our 
results show the promising potential of novel bioluminescence-activated PDT. 
Key words: Photodynamic Therapy, Bioluminescence, Photosensitizers, Resonance Energy Trans-
fer, Cancer, Photobiology, Photomedicine 
1. Introduction 
A variety of endogenous, administered, or ge-
netically incorporated molecules can be excited or 
altered upon absorption of a single nonionizing pho-
ton (450-700 nm). The light-induced chemical pro-
cesses are thermodynamically robust, because of the 
high activation energy, and energy-efficient because 
the downstream biochemical events, such as enzy-
matic reactions, can effectively amplify their biologi-
cal effects. Numerous treatment methods based on the 
photochemical processes have been developed, which 
include photodynamic therapy (PDT) [1-3], low-level 
light therapy [4] and collagen crosslinking [5], as well 
as optogenetics [6]. Despite the growing biomedical 
applications of the light-based techniques, a major 
common challenge has been the difficulty of deliver-
ing the activation light deep into the tissue. Owing to 
its intrinsic absorption and scattering [7], the penetra-
tion depth of visible light is no more than a several 
mm’s in tissue.[8] To date, the clinical use of optical 
techniques has been limited to superficial layers, such 
as the skin and retina, or the epithelial surfaces of 
organs that are accessible by catheters or endoscopes. 
 
Ivyspring  
International Publisher 
 Theranostics 2015, Vol. 5, Issue 8 
 
http://www.thno.org 
806 
An intriguing solution to this problem arises 
from the concept of internal light sources. Implanting 
fiber-optic light sources [9] and light emitting diodes 
[10, 11] could be a viable approach in some settings, 
but it requires invasive procedures. Among potential 
candidates [12], bioluminescence (BL) offers an at-
tractive alternative to solid-state optoelectronic de-
vices because the source molecules (i.e. enzymes and 
substrates) can be delivered minimal- invasively. BL 
has been widely used in optical imaging, but its po-
tential in therapies [13, 14] has been only recently 
recognized [15-18]. Theodossiou et al. has used a can-
cer cell line expressing firefly luciferase and observed 
efficient cell death in vitro when both photosensitizers 
and luciferin were administered into the cytosol [13], 
but this conclusion was later disputed [14]. Recently, 
Hsu et al. [15] obtained a reduction of tumor growth 
by using self-illuminating quantum dots (QDs) [19] 
and attributed the effect to bioluminescence reso-
nance energy transfer (BRET) [20-24] to photosensi-
tizers in the cytoplasm. Despite these encouraging 
results, however, the mechanism of cell killing has 
been speculative [16], and it remained controversial 
whether BL-induced PDT (“BL-PDT” hereinafter) can 
be effective given its much lower energy than the en-
ergy typically required for laser illumination in con-
ventional PDT. Yuan et al. reported significant treat-
ment effects of tumor [18] and fungus [25] by using a 
chemiluminescent molecule, luminol. While luminol 
has biocompatibility issues, such as their adverse ef-
fects on DNA and high affinity to serum albumin 
[26-28], bioluminescent molecules generally offer 
higher biocompatibility. 
Here, using self-illuminating conjugates of Rluc8 
(Luc) and QD (hereinafter Luc-QD) [19] and photo-
sensitizer chlorine e6 (Ce6) [15], we describe our 
finding that BRET-induced activation of Ce6 at the cell 
membrane, rather than inside cytosol, can lead to sig-
nificant cytotoxicity. Our experimental data provide 
insights into the mechanism, distribution, and thera-
peutic efficacy of BL-PDT in direct comparison to 
conventional PDT using laser irradiation-induced 
activation [29]. By intratumoral delivery of agents, we 
investigate the effects of BL-PDT on tumor growth in 
mice in vivo for three different cancer cell lines: CT26 
colorectal cancer cells, B16F10 melanoma cells, and 
LLC lung cancer cells. Furthermore, we demonstrate 
the feasibility of novel peritumoral BL-PDT, where the 
therapeutic agents are delivered to local lymph nodes 
(LNs) to ablate the cancer cells spread to the LNs lo-
cated at depths not accessible by external illumination 
of light. This work shows the benefit of BL-PDT for 
suppressing distant organ metastasis and extending 
animal survival. 
2. Materials and methods 
2.1. Synthesis of Luc-QD conjugates 
RLuc8 proteins were produced in E.coli LMG 
194 strain from pBAD-RLuc8 plasmid supplied from 
Dr. Gambhir in Stanford University [30]. RLuc8 pro-
teins were purified and extracted by immobilized 
metal ion affinity chromatography and anion ex-
change chromatography. N-(3-Dimethylamino-
propyl)-N’-ethylcarbodiimide hydrochloride (EDC, 
Fluka) was used to conjugate RLuc8 and carboxylated 
655-nm quantum dots (QD-655, Life Technologies), 
mixed with a ratio of 40:1 in solution [31]. The emis-
sion spectrum of QD-655 overlaps well with the ab-
sorption spectrum of Ce6. QD-655 has an amphiphilic 
polymer coating with a functionalized polyethylene 
glycol (PEG) linker. The Luc-QD conjugates were se-
lected by centrifuging (2.7 kg, 3 min, 4 °C) several 
times with 100 kD cutoff centrifugal filters (Pall). For 
consistent and maximum energy efficiency, Luc-QD 
was synthesized within a few hours before use.  
2.2. Transmission electron microscopy  
For imaging Luc-QD conjugates, 
glow-discharged carbon-coated 400 mesh copper 
grids (Electron Microscopy Science) either unstained 
or negatively stained with 0.75% uranyl formate solu-
tion were used. For cell imaging, at 30 min after CTZ 
injection CT-26 cells were fixed with 3% glutaralde-
hyde in 0.1 M cacodylate buffer (pH 7.2) containing 
0.1% CaCl2 for 2 h at room temperature. The cells 
were washed five times with 0.1 M cacodylate buffer 
at 4 °C and then post-fixed with 1% OsO4 in 0.1 M 
cacodylate buffer containing 0.1% CaCl2 for 2 h at 4 
°C. After rinsing with cold distilled water, the cells 
were dehydrated slowly with a series of ethanol and 
propylene oxide at 4 °C. Then, the samples were em-
bedded in Embed 812 resin (Electron Microscopy 
Science). After polymerization at 70 °C for 36 h, serial 
sections were cut by an ultramicrotome (Ultracut 
UC7, Leica) and mounted on formvar-coated slot 
grids (Electron Microscopy Science). The sections 
were stained with 4% uranyl acetate for 10 min and 
lead citrate for 7 min. Images were recorded with a 
FEI Tecnai T12 Bio-TWIN TEM operated at 120 kV 
with a 67,000× or 110,000× nominal magnification. 
2.3. BL-PDT of cells in vitro 
Murine Lewis lung cancer (LLC) and B16F10 
melanoma cells (ATCC) tagged with GFP were grown 
in DMEM with 10% FBS and 1% penicillin and strep-
tomycin. CT26 murine colon cancer cells (ATCC) were 
grown in RPMI media containing 10% FBS and 1% 
penicillin and streptomycin. Typically, 2 x105 cells 
were transferred to each well containing 200-µl 
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FBS-free medium in a 48-well plate. After 12 hours of 
incubation, the medium was changed with 200 µl 
FBS-free media, added with Ce6 (10 µg/ml, Santa 
Cruz Biotechnology), incubated for 3 h for accumula-
tion of Ce6 into the cells, and then changed to fresh 
FBS-free DMEM after washing twice with PBS. Con-
ventional PDT was conducted [32] by using a sin-
gle-spatial-mode laser (Shanghai Sanctity laser tech-
nology) with a center wavelength of 660 nm. A cus-
tom-built telescope was used to expand the laser 
beam to illuminate each well uniformly. The intensity 
level was adjusted by using neutral density filters. For 
BL-PDT, Luc-QD conjugates were administrated to 
the media and incubated for 5 min, and then 
h-coelenterazine (CTZ; Prolume) dissolved in 1% 
propylene glycol (Junsei) with cell specific media and 
50-mM (2-hydroxypropyl)-β-cyclodextrin was ad-
ministered to the well.  
2.4. In vitro analysis of cytotoxicity 
For cell viability imaging, Hoechst stain dye (500 
µg/ml, Sigma-Aldrich) was added to the medium at 4 
h after PDT, and cells were incubated for 5 min at 
37°C. Then, the cells were incubated with propidium 
iodide (25 µg/ml, Sigma-Aldrich) for 5 min at room 
temperature. The excitation laser power used in con-
focal microscopy was set to <1 mW at the sample to 
avoid any photo-induced effects on cell viability by 
the imaging light. MTT assay was carried out ac-
cording to the previously reported protocols [33, 34]. 
MTT (Invitrogen) was dissolved in pH 7.4 PBS and 
stored at 4°C. After PDT, the well plate was incubated 
at 37°C for 8 h. Then, the media was changed to 200 µl 
FBS-free media, 20 µl of 5 mg/ml MTT solutions were 
added to each well, and the well plate was incubated 
for 1 h at 37°C. After removing the media, 200 µl 
DMSO was added and stirred vigorously by pipetting 
to dissolve violet color formazan crystal completely in 
20 min, and 100-µl aliquots of the solution were 
transferred to a well. The absorbance at 540 nm was 
measured with an ELISA reader. 
2.5. Analysis of intracellular ROS  
For SOSG imaging, 100-µg SOSG reagent vial 
(Invitrogen) was dissolved in 660 µl methanol to make 
250 µM stock solution [35], and 12 µl of stock solution 
was added in the cell culture well to reach 15 µM final 
working concentration. After incubation for 5 min, 
BL- or laser-PDT was conducted as described above, 
and confocal images were taken during the proce-
dure. For DCFH-DA (Cell Biolabs) and lipid peroxi-
dation measurement (Abcam) [36, 37], cells in a 48 
well plate were washed three times gently with DPBS. 
Pre-made 20× DCFH-DA solution was mixed with 
FBS-free RPMI medium. The 1× DCFH-DA/RPMI 
solution as added to the well and incubated at 37 °C 
for 40 min. After removing the 1× DCFH-DA/RPMI 
solution, RPMI was added to the washed cell culture, 
and PDT was performed. After 30 min, the treated 
cells were washed, and 200 µl media and 200-µl 2× 
cell-lysis buffer were added and mixed thoroughly. 
After 5 min incubation, 150 µl of mixture was trans-
ferred to a microplate reader (Spectramax plus384), 
and the fluorescence at 530 nm (480 ex.) was meas-
ured in comparison to standard DCF concentrations. 
For lipid peroxidation study, cells before treatment 
and 10- and 30-min after treatment were homoge-
nized on ice with mixture of 300 µl MDA lysis buffer 
and 3 µl 100× BHT. The solution was centrifuged to 
remove insoluble material for 10 min (13 kg). 200 µl of 
the supernatant was mixed with 600 µl TBA solution 
and incubated for 60 min at 95 °C and cooled down to 
room temperature in ice bath for 10 min. 200 µl of the 
sample was transferred to the microplate reader, and 
the fluorescence intensity at 553 nm (ex. at 532 nm) 
was measured in comparison to various concentra-
tions of MDA standard solution. 
2.6. Intratumoral BL-PDT in vivo 
All animal experiments were approved from the 
Institutional Animal Care and Use Committee 
(IACUC) at KAIST and performed in compliance with 
the institutional guidelines. 2x106 CT-26 cells were 
injected subcutaneously into the flanks of 8-week-old 
BALB/cAnN.Cg-Foxn1 nu/CrliOri mice (Balb/c-nu), 
as previously described [38]. 1.5x106 LLC cancer cells 
or B16F10 cells were injected to wild-type C57BL/6 
mice (8 weeks old). At 4 hours after injection of Ce6 
(10 mg/kg) into the tail vein, the mouse was anesthe-
tized. For laser PDT, 660 nm laser light was irradiated 
on the tumor through the skin. For BL-PDT, Luc-QD 
(50 pmol) was injected intratumorally, and CTZ dis-
solved with Fuel-Inject (prolume) were administrated 
intravenously. Luminescence from CTZ was imaged 
with IVIS spectrum (Xenogen). The first treatment 
session was conducted at day 9, when the tumor 
volume became about 50 mm3. The size of the tumor 
was measured by using electric calipers, as described 
previously [39]. For histology and immunohisto-
chemistry, mice were sacrificed two days after 
BL-PDT, and the tumors were resected and fixed at 
4% paraformaldehyde (PFA) for 3 h. Paraf-
fin-embedded tumors were stained with hematoxylin 
and eosin (H&E) according to standard protocol. The 
other tumors were rinsed several times with PBS and 
stored with 30% sucrose for overnight for dehydra-
tion. For immunohistochemistry (IHC), the tumors 
were embedded in OCT solution and stored at -80 °C. 
Frozen sections were made with a thickness of 20 µm 
by using a microtome. Hamster CD31 antibody (1:200, 
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Santa Cruz) and rabbit caspase-3 antibody (1:300, 
R&D Systems) were used as primary antibody for 
IHC. Hamster FITC (1:1000, Santa Cruz) and rabbit 
cy-3 (1:1000, Santa Cruz) were used as secondary an-
tibody. The tissue slides were stained with APR-648 
(BioActs), which is a Cy-5 labelled phosphatidylserine 
recognizing peptide, and 4',6-diamidino-2- 
phenylindole (DAPI, Life Technologies).  
2.7. Peritumoral BL-PDT to treat LN metastases 
(CT26 and LLC) 
To make LN metastasis models, 1.5x106 CT26 
cells or LLC cells were injected into the right-side 
footpad of 8-week-old Balb/c-nu or C57BL/6 mice, 
respectively. At day 11 after tumor injection, 12 µg 
Ce6, 30 pmol Luc-QD conjugates and 70 nmol CTZ 
were injected sequentially with 10 min intervals into 
the dorsum of the foot. Two days after the treatment, 
the popliteal LN was isolated from the mouse, fixed 
with 4% PFA in PBS, and paraffinized. TdT-mediated 
dUTP Nick-End Labeling (TUNEL) assay (Promega) 
was conducted. For in situ apoptosis detection 
(ApopTag; Chemicon), hydrated tissues after 
de-parafinization were incubated with proteinase K. 
Reaction buffer containing biotinyl-UTP, deoxyribo-
nucleotide transferase, and streptavidin-rhodamin 
was sequentially added. For immunostaining, antigen 
retrieval was achieved by boiling the tissues three 
times with 0.1% citrate buffer in a microwave oven. To 
minimize non-specific reaction, the tissues were in-
cubated with H2O2 and then with PBS-based blocking 
buffer containing 4% BSA and 0.1% triton X-100. For 
detecting metastatic tumor cells in LN, anti-pan cy-
tokeratin antibody (1:200, Abcam) and anti-mouse cy3 
antibody (1:1000, Santa Cruz) were used. Cellular 
nuclei were stained with DAPI at the concentration of 
0.1mg/ml. Two weeks after BL-PDT, or day 25, the 
mice were sacrificed, and both lungs were isolated 
and fixed with 4% PFA. After fixation, lungs of CT26 
bearing mice were embedded with paraffin, and the 
paraffinized tissues were sectioned at interval of 100 
µm. The number of metastases at six sectioned slides 
around mid-section lungs per mouse was counted 
and analyzed statistically. The surface lung metasta-
ses of LLC bearing mice were manually counted, and 
the weight of lungs was measured [40].  
2.8. In vivo treatment of lymph-node metas-
tases (B16F10) 
1.5x106 B16F10 melanoma cells were injected 
subcutaneously into the footpad of 8-week-old 
C57BL/6 mice. BL-PDT was performed at day 21 after 
implantation by injecting 12 µg Ce6, 30 pmol Luc-QD 
conjugates and 70 nmol CTZ sequentially with 10 min 
intervals into the peritumoral dorsum of the foot. Two 
days after the treatment, the popliteal LNs of the 
mouse were fixed with 1% PFA in PBS and dehy-
drated with 20% sucrose. After rinse with PBS, re-
sected LNs were embedded in tissue freezing medium 
(Leica). Mid-sectioned LNs were incubated with 
blocking solution containing goat serum (Jackson 
ImmunoResearch). The sectioned tissues were incu-
bated overnight with one of more of the following 
primary antibodies (1:200): anti-vascular endothelial 
growth factor receptor 3, goat polyclonal (VEGFR3: 
R&D); anti-CD31, hamster monoclonal (Millipore); 
anti-Melan-A, mouse polyclonal (Abcam); and an-
ti-caspase-3, rabbit polyclonal (R&D). After several 
rinse with PBS, the sectioned tissues were incubated 
for 2 h with one or more of the following secondary 
antibodies (1:1000): anti-goat cy3 (invitrogen), an-
ti-hamster cy5 (Jackson ImmunoResearch), an-
ti-mouse cy3 (Jackson ImmunoResearch), and an-
ti-rabbit FITC (Jackson ImmunoResearch).  
2.9. Statistical analysis 
Error bars represent standard deviation (s.d.) 
from the mean. Data were analyzed by Student t-test, 
ANOVA with SPSS version 18. P-values of <0.05 were 
considered statistically significant. 
3. Results 
3.1. Mechanism of activation of photosensitiz-
ers 
Although external illumination offers conven-
ience, there are two fundamental drawbacks. One is 
light propagation loss. To induce meaningful photo-
chemical effects, irradiance greater than 1 mW/cm2 is 
required at the target. The intrinsic optical attenuation 
in the skin is 5-10 dB per in the visible spectrum (see 
Supplementary Material). Considering the maximum 
permissible exposure level (1 W/cm2) at the skin sur-
face, the effective therapeutic depth is less than sev-
eral mm’s, which is consistent with experiments. The 
second drawback is the relatively weak interaction 
between light and molecule (Fig. 1). The absorption 
cross-section (σa) of Ce6, an efficient photosensitizer, 
is 2.3x10-16 cm2 at λ=660 nm (calculated from the ex-
tinction coefficient of 59,000 M-1 cm-1). This means 
that, at 1 mW/cm2, each Ce6 molecule absorbs, statis-
tically, less than one of incoming 106 photons per sec 
in a minimum diffraction-limited area of 0.1 µm2.  
The electric field, Ε, at a distance, r, from an ex-
cited BL molecule can be expressed as:  
 …(1) 
where k=2π/λ and p is the dipole moment of the light 
source [41]. The first term in the parenthesis describes 
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far-field radiation. The second term represents the 
near-field non-radiative field with intensity decaying 
with 1/r6, which is responsible for Förster resonance 
energy transfer (FRET). The efficiency of FRET, η, is 
expressed as [42]:  
       …(2) 
where QY is the quantum yield of the donor and R0 is 
a Förster radius, which is typically 5-10 nm. From Eq. 
(1), the intensity ratio of the non-radiative to the radi-
ative field (the ratio of the ensemble square of the first 
and second terms) can be shown to be , 
where = 2/3 was used [42]. For r <10 
nm, the intensity ratio is much greater than unity; for 
example, the ratio is 1.3x105 for r=5 nm and λ=660 nm.  
For η=100%, one substrate-enzyme reaction—i.e. 
one “BL photon”—is sufficient to activate one Ce6 
molecule. (For η=50%, two BL photons can activate 
one Ce6 molecule.) Therefore, the near-field interac-
tion by BRET energy sources can solve the drawbacks 
of the conventional approach using far-field radiation 
(Fig. 1). Considering that the probability of one BL 
photon is absorbed at a distance of R0 is 50%, the ef-
fective non-radiative absorption cross-section of a 
FRET acceptor may be defined to be 2πR02, whereas 
the radiative cross-section is σa. Therefore, their ratio 
2πR02/σa is ~6830, which represents the advantage in 
the efficiency of FRET-induced over radia-
tion-induced activation. 
 
 
Figure 1. Radiation- vs. resonant energy transfer-induced activation 
of photosensitizers. Conventional light delivery by external illumination 
suffers from superficial therapeutic depths due to the small absorption 
cross-section of a molecule and the optical propagation loss in tissue. By 
contrast, the resonance energy transfer from an injectable, or biologically 
producible, bioluminescence source can activate a target molecule more 
effectively due to strong near-field interaction, in the regions inaccessible by the 
external light.  
 
3.2. Measurement of BRET energy 
We have designed an experiment using Luc-QD 
as the BL source and amphiphilic Ce6. Our hypothesis 
is that, upon administration of CTZ, the generated BL 
energy is transferred to nearby Ce6 and, subsequent-
ly, the activated Ce6 triggers membrane damage that 
results in cell killing [43, 44] (Fig. 2a). This cascade of 
FRET events does not involve radiative emission of 
photons (Supplementary Fig. 1). The Luc-QD conju-
gates were synthetized by covalently conjugating 
10-20 RLuc8 molecules onto the polymeric coat of QD, 
as confirmed by TEM (Fig. 2b and Supplementary 
Fig. 2a). When mixed with CTZ, Luc-QD solution 
emits red fluorescence, whereas the original BL from 
RLuc8 has a blue-green color (Fig. 2c). The BRET effi-
ciency from RLuc8 to QD was 60-65% (Fig. 2d). 
Time-lapse confocal fluorescence microscopy showed 
that Luc-QD conjugates were highly concentrated 
around the external surface of cells without entering 
the cytoplasm (Fig. 2e and Supplementary Fig. 3), as 
consistent with TEM images (Supplementary Figs. 
2b-d). The high affinity, dense distribution, and short 
distance of Luc-QD to the cell membrane are critical 
for activating Ce6 at the cell membrane (Fig. 2f). 
When a culture well containing 2x105 murine colo-
rectal cancer CT26 cells in monolayer (1 cm2) was il-
luminated with 660 nm laser light with 2.2 mW, the 
difference of transmission through Ce6-incubated 
versus non-incubated cells was 13 µW (Supplemen-
tary Fig. 4a). This means that a total 2x108 photons/s 
are absorbed per cell. From the absorption 
cross-section of Ce6, the concentration of Ce6 is cal-
culated to be about 100 µM (6x107 Ce6 per cell), and 
these molecules collectively are activated 4x107 times 
per min by the laser flux.  
The average intermolecular distance of ran-
domly distributed Ce6 is ~50 nm in the cell. Modeling 
a cell as a sphere with a radius (R) of 10 µm with 
uniform concentration of Ce6, within 10 nm (R0) from 
the external surface of the cell membrane we estimate 
that 0.33% (=0.33 R0/R) or 2x105 molecules are pre-
sent. 50 pmol (3x1013) Luc-QD conjugates were ad-
ministered into the medium. Due to the high concen-
tration of Luc-QD surrounding the cells, the majority 
of Ce6 at the cell membrane is expected to be within a 
FRET radius (<10 nm) from one or more donor mol-
ecules. After the incubation of Ce6 for 3 h and a sub-
sequent 5-min incubation of Luc-QD, 28 nmol 
(1.7x1016) CTZ were added. Luminescence appeared 
immediately but decreased rapidly (Fig. 2g and Sup-
plementary Fig. 4b). According to our simple model 
(Supplementary Fig. 5), the initial 1/t2 type decay 
(0-1 min) may indicate a degradation of Luc-QD as 
they react with CTZ. This accounts for our observa-
tion that a secondary injection of additional CTZ 
generated weaker luminescence. The total emitted 
luminescence for 1 min was about 180 µJ (6x1014 
photons). The difference of total luminescence from 
Ce6-incubated vs. non-incubated cells was 14 µJ. This 
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corresponds to 70 pJ or 3x108 “BL photons” per cell, 
which represents the total energy transferred to 
nearby Ce6. The number of activated Ce6 is thus 3x108 
per min, more than 4x107 per min calculated above for 
laser illumination for 1 min at 2.2 mW/cm2. There-
fore, this quantitative analysis suggests that BRET 
energy in the order of 100 µJ could generate stronger 
photochemical activation in the cellular membrane 
than laser energy in the order of 100 mJ. 
3.3. BL-PDT induces cytotoxicity at the cellu-
lar membrane 
We used MTT assay to measure the cytotoxicity 
induced by BL-PDT on CT26 cells in vitro. The cell 
death increased with increasing amount of CTZ (Fig. 
3a). Negligible cytotoxicity was measured with Ce6 
only or without Ce6 (Luc-QD and CTZ), or when 
Rluc8 replaced Luc-QD. For comparison, CT26 cells in 
monolayer were treated with a 660 nm laser for 3 min 
at various intensity levels (Fig. 3b). Little cytotoxicity 
was observed at intensities lower than 0.1 mW/cm2. 
At 2.2 mW/cm2, the treatment effect with 3-min ex-
posure was similar to that of BL-PDT (28 nmol CTZ), 
which is consistent with our estimation above. Similar 
result was obtained for B16F10 melanoma cells tagged 
with GFP (Supplementary Fig. 6). Time-lapse mi-
croscopy showed typical swelling and rounding of 
cells and damaged mitochondrial granules during BL- 
and laser-PDT (Fig. 3c and 3d). These changes con-
tinued for 30 min, longer than the duration of BL 
emission (Supplementary Fig. 7). Imaging with 
DNA-binding membrane-permeable Hoechst and 
impermeable propidium iodide (PI) dyes revealed 
some striking features of BL-PDT (Fig. 3e). The dam-
aged cells indicated by PI-positive nuclei were sur-
rounded by large amount of Luc-QD. By contrast, 
PI-negative cells had negligible Luc-QD around their 
cellular membrane. Unlike BL-PDT, laser-PDT did not 
cause nucleus disintegration (Supplementary Fig. 8). 
TEM taken 30 min after BL-PDT showed membrane 
rupture (Fig. 3f). 
Generation of singlet oxygen and reactive oxy-
gen species (ROS) is a hallmark of PDT. We expect 
that the activation Ce6 by BRET generates ROS and 
causes lipid peroxidation at the cell membrane, and 
subsequent cell death signaling following the mem-
brane damage generates a significant amount of ROS 
in the cytosol that can be detected by standard cellular 
assays. Indeed, significant intracellular ROS was 
measured by dichloro-dihydro-fluorescein diacetate 
(DCFH-DA) in BL-PDT, as well as laser-PDT (Fig. 3g). 
Measurement of malondialdehyde (MDA) confirmed 
lipid peroxidation (Fig. 3h), evidencing ROS-induced 
membrane damages [45]. The amount of MDA in-
creased with time after the treatments. Time-lapse 
microscopy (with 1 min interval) using mem-
brane-impermeable probe, singlet oxygen sensor 
green (SOSG), suggested that significant membrane 
damage occurred within the first 1 min after CTZ in-
jection, starting with the cells with more Luc-QD at 
their membranes (Fig. 3i). After 10 min, most treated 
cells, but not controls, showed strong SOSG signals in 
the cytoplasm and round morphology (Supplemen-
tary Fig. 9). The relatively extended duration of ROS 
generation and cellular changes compared to the du-
ration of BL emission (<1 min) suggests the involve-
ment of intracellular signaling pathways, such as 
ROS-induced ROS release by mitochondria [46]. 
 
Figure 2. The design and principle of BL-PDT. a, Illustration of the proposed mechanism based on resonance energy transfer at cellular membrane. b, TEM 
image of Luc-QD conjugate. c, Luminescence from RLuc8 and Luc-QD. d, Emission spectrum of Luc-QD. The BRET ratio was calculated from the ratio of the area 
under curve of RLuc8 emission between 390 and 600 nm and that of QD emission between 600 and 710 nm. e, Confocal images of red fluorescence from QD, 
showing the distribution of Luc-QD outside cells (CT26 cells; green: intracellular dye). f, Confocal fluorescence image of Ce6, showing its distribution in the cytosol. 
g, Luminescence power generated after administration of 28 nmol CTZ. Scale bars in e and f, 50 µm. 
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Figure 3: Effects of BL-PDT on cancer cells in vitro. a, MTT analysis of CT26 cells treated with BL-PDT. b, The efficiency of conventional PDT at different laser 
powers. c, Time-lapse images of LLC-GFP cells during BL-PDT. d, Time-lapse images of LLC-GFP cells during laser-PDT. Control cells without laser irradiation 
showed no change in GFP fluorescence. e, Confocal image of LLC cells 4 h after BL-PDT. Damaged cells with PI-positive nuclei are surrounded heavily by Luc-QD 
(squares), whereas live cells with intact PI-negative nuclei have no or less Luc-QD around their cell surfaces (arrows). f, TEM image showing membrane disruption and 
leak of intracellular components after BL-PDT. g, DCF assay to measure intracellular ROS level. h, Lipid peroxidation assay. i, Time-lapse confocal images of SOSG 
and Luc-QD. Cells surrounded by more Luc-QD show earlier infiltration of SOSG. ANOVA test p values: * <0.05, ** <0.01. Error bars, s.d. Scale bars, 50 µm in c and 
d; 100 µm in e and i. 
 
3.4. BL-PDT suppresses tumor growth in mice 
in vivo 
To test the effect of BL-PDT on tumor growth, we 
used tumor implant models. CT26 cells were injected 
into Balb/c nude mice at both flanks subcutaneously. 
When the tumor volume reached at about 50 mm3, the 
first treatment was conducted by systemic delivery of 
Ce6. After 4 hour of incubation, Luc-QD (3x1013) was 
injected directly into the tumor, and after 5-10 min, 
CTZ (60-300 nmol) was injected intravenously (Fig. 
4a). The luminescence was visible for more than one 
hour after CTZ injection (Fig. 4b). This emission du-
ration is much longer than in vitro settings (Fig. 2h) 
presumably because of the longer diffusion time of 
CTZ in the tumor tissue. In the treatment group that 
received three sessions of BL-PDT over a week, but 
not the untreated and sham-treated groups, showed 
the decrease of tumor growth. The growth inhibition 
increased, but not statistically significantly, with the 
administered amount of CTZ from 1 to 4 mg/kg (Fig. 
4c). A nine-session (N=9) treatment resulted in a near 
complete inhibition of tumor growth (Fig. 4d). The 
regression and necrosis of tumor was visibly apparent 
(Fig. 4e). H&E staining of the major organs, including 
the liver, kidney and bladder, did not show any ap-
parent adverse effect of BL-PDT. The growth inhibi-
tion was similar or better than conventional PDT 
(three sessions; N=3) by transdermal illumination (660 
nm, 5 mW) for 3 min (Fig. 4f). When the laser light 
was illuminated through a 5-mm-thick pad of soft 
tissue, no therapeutic effect was observed even with 
higher laser powers (Fig. 4f). Apoptotic cell death was 
observed across the entire tumor (Fig. 4g and Sup-
plementary Fig. 10)  
3.5. Treatment of lymph-node metastases by 
local delivery 
Cancer cells spread to local and regional LNs 
and also in-transit cells in peritumoral lymphatic 
vessels increase the risk of recurrence in the breast. It 
is challenging to eradicate these cells by conventional 
PDT because of the limited light penetration. BL-PDT 
offers a potential to treat LN metastasis by local de-
livery of the agents via the peritumoral lymphatic 
draining system and activation by subsequent ad-
ministration of CTZ (Fig. 5a). To test the therapeutic 
effect of BL-PDT on LN metastases, we used footpad 
implant models, in which the popliteal LN (p-LN) is 
the sentinel LN. 1.5x106 CT26 cells were injected into 
the footpad of Balb/c nude mice. Eleven days after 
tumor cell inoculation, the primary tumor was grown 
to a size of several millimeters at the injection site (Fig. 
5b), and tumor cells were found in the p-LN with al-
most 100% efficiency. At day 11, Ce6 (50 nmol) was 
injected into the dorsum of the foot in the vicinity of 
the tumor, which allows effective draining of the 
agents to the p-LN through the lymphatic vessels (Fig. 
5c). After 10 min, Luc-QD (30 pmol) was injected into 
the peritumoral region, which immediately drained to 
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the LN. After 10 min, CTZ (70 nmol) was injected, 
which generated luminescence almost instantly. The 
luminescence intensity decreased slowly over time 
(Fig. 5d and Supplementary Fig. 11). In addition to 
the sentinel LN, depending on the injection condition, 
it was possible to deliver the agents to the secondary 
LN, such as lumbar and inguinal LNs, through lym-
phatic drainage (Supplementary Fig. 12). Histologic 
analysis confirmed the enlarged size and lymphan-
giogenesis in the p-LN and increased pancytokeratin 
positive metastatic tumor cells at day 13 in untreated 
mice (Fig. 5e). BL-PDT resulted in destruction of the 
lymphatic structure in the LN and cell death indicated 
by in situ TUNEL along the lymphatic vessels (Fig. 5f). 
The pancytokeratin positive metastatic tumor cells 
were 10 fold decreased after BL-PDT (Fig. 5g).  
3.6. Reduction of melanoma cells in the senti-
nel and secondary LNs 
To test BL-PDT for orthotopic melanoma, 1.5x106 
B16F10 cells were injected into the footpad of 
wild-type C57BL/6 mice. BL emission from the p-LN 
was confirmed, although it was less bright than in the 
CT-26 bearing nude mice due to the presence of hair 
and high melanin in the tumor cells (Fig. 6a). BL-PDT 
was performed 21 days after implantation. At day 23, 
the popliteal and inguinal LNs were harvested from 
both treated and untreated groups, sectioned, and 
examined by immunohistochemistry. The untreated 
p-LN had a considerable number of tumor cells, in-
dicated by melan-A surface antigen, scattered in mul-
tiple groups throughout the paracortex and medulla 
(Fig. 6b). The treated p-LN exhibited several distinct 
consequences of BL-PDT including the remarkable 
increase of apoptotic cell deaths throughout the cortex 
and paracortex (Fig. 6c). In these regions, the tumor 
vessels and lymphatic sinuses appear to have been 
severely disintegrated (Fig. 6d). The amount of me-
lan-A signal decreased to a half after the treatment in 
the p-LNs (Fig. 6e). The effects of BL-PDT were not 
limited to sentinel LN. Tumor cells were also found at 
inguinal LNs in the untreated mouse, particularly 
along the lymphatic vessels (Fig. 6f). At inguinal LN 
in the treated mouse (Fig. 6g), considerable apoptosis 
signals were measured in the paracortex and medulla. 
Notably, the number of melanoma cells at inguinal 
LN was significantly reduced in the treated compared 
to untreated mice (Fig. 6h).  
 
 
Figure 4. Effects of BL-PDT on tumors in vivo. a, Luminescence (575-650nm) from tumors injected with Luc-QD (50 pmol i.t.) and CTZ (28 nmol i.v.). b, 
Luminescence intensity from the tumor over time. c, Tumor growth curves for various treatment conditions. Arrows indicate the three sessions of BL-PDT. d, 
Tumor growth curves for extended BL-PDT protocols with 2-3 day treatment intervals (arrows). e, Photos of mice (at day 23) treated 0, 3, and 9 times, respectively. 
f, Tumor sizes measured at day 30 for control, sham-treated, BL-, and laser-PDT-treated mice (calculated from the data in b: N=3 or N=9 indicates groups that 
received three or nine treatment sessions.) g, Immunohistology with APR648 indicating apoptotic cell death within a tumor. Scale bars, 1 mm in (g). Error bars, mean 
+/- s.d. Two-sided Student test p values: * <0.05, ** <0.01, *** <0.001. 
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Figure 5: Treatment of lymph-node metastases. a, A schematic of LN metastasis and BL-PDT procedure. b, Photo of a mouse with CT-26 tumor grown in the 
footpad at day 11. c, Fluorescence image after injection of Ce6 into the foot. Draining Ce6 visualizes the lymphatic vessel and the popliteal LN (p-LN). d, Time-lapse 
luminescence images after CTZ injection into the dorsum of the foot. Strong luminescence is generated from the p-LN. e, Histology images of untreated LN sections 
harvested at day 13, stained with H&E, TUNEL, and pancytokeratin. f, Images of LN sections harvested at day 13, two days after BL-PDT, stained with H&E, TUNEL, 
and pancytokeratin. Cell death along the expanded lymphatic vessels is evident. f, Integrated pancytokeratin signals within the untreated and treated LN’s. 
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Figure 6: Treatment of lymph-node metastases. a, BL image of a C57/BL6 mouse with B16F10 tumor in the footpad (day 21), after injection of Luc-QD and 
CTZ into the foot. b, IHC images of p-LN sections harvested from an untreated mouse at day 23, stained for blood vessels (CD31), lymphatics (VEGFR3/CD31), 
melanoma cells (melan-A), and apoptosis (caspase-3). Strong green autofluorescence indicates germinal centers. c, Images of p-LN sections harvested from a treated 
mouse at day 23, two days after BL-PDT. d, Images of the regions marked in b and c. Arrows indicate damaged blood vessels. e, Integrated melan-A fluorescence 
magnitudes of the untreated (U) and treated (T) p-LNs. f, Inguinal LN sections harvested from the untreated mouse. g, Inguinal LN sections harvested from the 
treated mouse. h, The regions marked in f and g. Scale bars, 500 µm. Error bars, s.d. **, Kruskal-Wallis test p <0.01.  
 
Figure 7. Therapeutic effects of LN BL-PDT on animal survival and lung metastasis. a. Kaplan-Meier survival curve of CT26 bearing mice. b. H&E stained 
images of lung harvested 14 days after LN PDT. Arrows indicate small nodules in treated mice (top) and larger nodules with the sign of metastatic infiltration 
(bottom). Scale bar, 1 mm. c. The total number of metastatic lung nodules found from each animal group (6 lung sections per mouse, 12 mice). d. Kaplan-Meier 
survival curve of LLC-GFP bearing mice. e. Photographs of the lungs harvested at day 25. Circles indicate macroscopic metastatic nodules. f. The numbers of lung 
surface metastases. g. The weights of the lungs. *, Kruskal-Wallis test p <0.05; **, p <0.01. 
 
3.7. LN PDT reduces distant metastasis and 
improves animal survival  
To assess the effects of the LN treatment on dis-
tant metastasis, the lungs from treated (n=13) and 
untreated (n=12) animals were harvested 25 days after 
implantation of CT26 cells and 14 days after LN 
BL-PDT. Four mice of the untreated group died by 
day 25, where as 100% of the treated mice survived 
(Fig. 7a). The increase of survival time for the treated 
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animals was statistically significant. Histology of the 
lung tissues showed that the metastatic lung nodules 
in the treated mice were substantially smaller than 
those in the untreated survived mice (Fig. 7b). The 
number of lung nodules was significantly smaller in 
the treated group (Fig. 7c). We also performed the 
same experiment with LLC bearing mice in a treated 
(n=10) and untreated (n=10) groups. By day 25, 3 un-
treated mice died whereas none died from the treated 
group (Fig. 7d). The apparent size of the tumor nod-
ules in the surface of the lung was significantly less in 
the treated animals (Fig. 7e and Supplementary Fig. 
13). The number of visible metastasis in the lung sur-
face was less in the treated mice (Fig. 7f). The weight 
of the lung was also smaller in the treated mice (Fig. 
7g). These results indicate that LN PDT effectively 
reduced distant lung metastasis and extended the 
survival time of tumor-bearing animals.  
4. Discussion 
Clinically, conventional PDT has not been used 
to treat macroscopic tumors and metastases mainly 
due to the need of light activation. BL-PDT can solve 
this limitation by allowing the photochemical activa-
tion energy to be delivered by the transport of mole-
cules rather than electro-magnetic radiation. Our re-
sults showed that BRET-induced activation at the cell 
membrane induced significant cytotoxicity. Like 
conventional PDT, the cytotoxicity mechanism of 
BL-PDT is based on the generation of reactive oxygen 
species and singlet oxygen from photosensitizers. 
This mechanism is distinctively different from those 
employed in chemotherapy, which attacks cancer cells 
by interrupting processes, or inhibiting substances, 
necessary for cellular replication. Although the gen-
eral mechanisms of drug resistance would apply to 
PDT, the degree of resistance is far less than those 
encountered in chemotherapy, and no cross-resistance 
between PDT and chemotherapy has been reported 
[47]. For example, a protective mechanism such as 
repair to DNA damage, which can cause 
chemo-resistance, is limited in PDT [48, 49]. Because 
of the minimal cross-resistance, PDT is synergistic 
with chemotherapy [50, 51] and has shown to be ef-
fective in treating chemo-resistant [48, 52, 53] and 
multidrug resistant cancer [54-56]. Therefore, BL-PDT 
may be a modality in combinational therapy to treat 
chemo-resistant triple-negative breast cancer [57] or 
radiation-resistant cancers, such as metastatic mela-
noma. 
Ce6 localizes in the cell membrane, intracellular 
vesicles and other organelles including mitochondria 
and lysosomes [58-60]. In the BL-PDT technique 
demonstrated here, the primary site of activation of 
Ce6 is the cell membrane. The activated Ce6 generates 
ROS, and the generated ROS induce lipid peroxida-
tion of the cell membrane. Lipid peroxidation de-
structs the integrity of cellular membrane, which 
disrupts the intracellular homeostasis. Consequently, 
necrosis is induced as a cell death process. In conven-
tional laser-induced PDT, it has been shown that it is 
sufficient to kill cancer cells with laser PDT by using 
photosensitizers located only within cell membranes 
[61, 62] or extracellular photosensitizers attached to 
cellular membranes [43, 63]. Conventional PDT using 
membrane-targeted genetically encoded photosensi-
tizers has shown more effective and faster cytotoxicity 
through lipid peroxidation compared to conventional 
PDT using mitochondria targeted genetically encoded 
photosensitizers [61, 64].  
Although the cell membrane is an effective target 
for BL-PDT, we expect that simultaneous intracellular 
activation of photosensitizers would enhance cyto-
toxicity. Cell death mechanisms depending on the 
subcellular localization of photosensitizers have been 
extensively studies, including the biological effects 
following mitochondrial photosensitization [65-67]. 
For more efficient BL-PDT, one attractive approach is 
to develop conjugates of bioluminescent molecules 
and photosensitizers as direct BRET pairs. A number 
of luciferases and photosensitizers with reasonably 
good spectral overlaps are available, such as RLuc8.6 
(emission: 490-590 nm) [68] and Rose Bengal (absorp-
tion 520-560 nm) [69]. These molecules can be chemi-
cally conjugated and delivered together. Such conju-
gates can maximize the BRET-induced activation of 
photosensitizers.  
The BL-PDT agents used here and previously do 
not have designed-in specificity to cancer cells. A va-
riety of tumor-targeted drug delivery techniques de-
veloped for PDT and other molecular therapies can be 
adopted for BL-PDT. The BL-PDT agents may be 
combined with monoclonal antibodies (mAbs) against 
specific biomarkers or RGD peptides to enable tar-
geted BRET-induced photoimmunotherapy (PIT) [43, 
70, 71]. More sophisticated designs, such as prote-
ase-cleavable quenchers, may be employed to increase 
tumor specificity. Some BL molecules require cofac-
tors, such as Ca2+ and adenosine triphosphate (ATP), 
which may offer methods to couple with specific sig-
naling pathways and metabolic activities. The de-
pendence of BRET efficiency on distance (~r–6) may be 
used to target specific molecular interactions [20-24]. 
Since BL-PDT uses non-toxic agents prior to activa-
tion, unlike chemotherapeutic agents, strategies based 
on molecular transport and pharmacokinetics, such as 
optimizing the time delay between the luciferase and 
luciferin injections, may enhance the target specificity, 
minimizing damages to normal tissues. Advanced 
drug delivery systems may be employed to enable 
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systemic delivery of the BL molecules. 
Resection of peritumoral LNs is frequently per-
formed during surgery, but this procedure can cause 
complications such as lymphedema, a lifelong chronic 
condition that is caused by the disruption of the nor-
mal drainage pattern [72]. BL-PDT offers an alterna-
tive strategy to manage LN metastases without dis-
rupting the LNs, and this treatment can be particu-
larly useful in conjunction with diagnostic BL imaging 
[73]. In our protocol of LN PDT, the primary tumor is 
little affected because the therapeutic agents are ad-
ministered at the peritumoral dorsum of the foot. Our 
data showed a considerable reduction of cancer cells 
spread to both sentinel and secondary regional LNs. 
This effect is likely to be responsible for the significant 
reduction of distant metastasis and the improvement 
of animal survival, although it is not yet clear whether 
this result is solely due to cell deaths occurred in situ 
by BL-PDT or contributed by reduced metastasis of 
tumor cells during the two days after the treatment 
possibly owing to any reduction in afferent lymphatic 
drainage to the LNs. Whole-body BL imaging con-
ducted four days after BL-PDT showed a partial de-
struction of upstream lymphatic vessels around the 
primary tumor. (Supplementary Fig. 14). This also 
suggests the possibility of eradicating in-transit cancer 
cells in the lymphatic vessels by BL-PDT [74]. Can-
cer-targeted BL-PDT agents are expected to minimize 
the damage to the lymphatic vessels and ensure the 
recovery of the normal function of the lymphatic sys-
tem. The ability to eradicate remaining cancer cells 
more thoroughly with minimal damage to normal 
tissue is highly significant because it can lower local 
recurrence, mortality, morbidity, and cost-burden of 
breast cancer patients. Further research to test the 
potential of BL-PDT as adjuvant therapy to treat LN 
metastasis is warranted.  
In conclusion, BRET energy-induced activation 
is a new paradigm of how we generate photochemical 
effects in deep regions that cannot be reached by ex-
ternal optical illumination. The use of internal energy 
source can have far-reaching applications beyond 
PDT. Deep-tissue photochemical activation via BL 
molecules may offer new possibilities in the field of 
Photomedicine for a wide range of applications from 
cancer treatment, to immune and brain stimulation, 
and to in-body sensing and genetic control.  
Supplementary Material  
Supplementary Figures 1-14. 
http://www.thno.org/v05p0805s1.pdf 
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